Recruiting

New combination treatment for liver cancer that cannot be surgically removed

Plain-English translation of NCT06371157 on ClinicalTrials.gov ↗ · Source last updated March 2025 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing whether combining two medications—cadonilimab () and —together with a standard procedure called TACE (a catheter-based treatment that delivers chemotherapy directly to the tumor) can help people with inoperable liver cancer live longer and healthier. Some participants will receive both medications plus TACE, others will receive just TACE, and a third group will receive one medication plus TACE. The goal is to see if adding these medications improves outcomes compared to TACE alone.

Liver cancer that cannot be removed with surgery or transplant is very difficult to treat, and current options have limited effectiveness. Researchers believe that combining this medication with the standard TACE procedure may help the body fight the cancer more effectively.

Do you qualify?

You likely qualify if…

you have been diagnosed with hepatocellular carcinoma (liver cancer) confirmed by imaging or biopsy
your cancer has not spread to other parts of your body
your cancer cannot be treated with surgery, transplant, or ablation, but can be treated with TACE
you have good liver function (Child-Pugh class A)
you are in good enough health to handle treatment (ECOG performance status 0 or 1)

You likely don't qualify if…

you have previously received a liver transplant
you have a history of hepatic encephalopathy (a serious liver disease complication)
you have uncontrolled high blood pressure
you had blood clots in your legs within the last 3 months
you had serious bleeding events in the last 6 months

What participation looks like

You will be randomly assigned to one of three groups: one receiving both new medications plus TACE, one receiving just TACE, or one receiving one medication plus TACE. You will have regular clinic visits for monitoring, blood tests, and imaging scans to track how well the treatment is working. The trial involves multiple visits over time as you receive treatment and follow-up care.

AI-generated summary from trial data · Jun 12, 2026 · Not medical advice

Trial locations(4 sites)

China

Henan Cancer Hospital, Zhengzhou, Henan

Hunan Cancer Hospital, Changsha, Hunan

Zhongda Hospital Southeast University, Nanjing, Jiangsu

Zhejiang Cancer Hospital, Hangzhou, Zhejiang